Compliance News | November 11, 2025 The administration, together with pharmaceutical manufacturers Eli Lilly and Novo Nordisk, announced an agreement to lower prices and expand access to glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss for those in the Medicare Part D and Medicaid programs as well as direct-to-consumer (DTC) purchasing
There are no widespread, serious drug interactions reported at typical doses, but medical history matters
Many patients prescribed semaglutide (Ozempic, Wegovy, Rybelsus) wonder whether they can drink alcohol while taking this medication
Glow Up patches are discreet and comfortable, making them a convenient solution for daily use
The injectable weight loss medication garnered significant attention following clinical trials when participants lost up to 20% of their body weight
Our initial 12-week program utilizes a gradual titration approach, allowing your dose to be carefully increased over time